传染科指南

订阅

MedSci主页 / 所有栏目 / 传染科指南

日本关于 COVID-19 药物管理的快速/实时建议：更新指南（2021 年 9 月）

2021-11-16 日本脓毒症和感染性休克管理临床实践指南 Acute Medicine & Surgery

药物管理Covid-19

自 2020 年初以来，2019 年冠状病毒病 (COVID-19) 已在全球范围内蔓延，但仍然没有解决的迹象。

中文标题：

日本关于 COVID-19 药物管理的快速/实时建议：更新指南（2021 年 9 月）

英文标题：

Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021)

发布机构：

日本脓毒症和感染性休克管理临床实践指南

发布日期：

2021-11-16

简要介绍：

自 2020 年初以来，2019 年冠状病毒病 (COVID-19) 已在全球范围内蔓延，但仍然没有解决的迹象。日本脓毒症和感染性休克管理临床实践指南 (J-SSCG) 2020 特别委员会利用创建 J-SSCG 的经验制定了日本关于 COVID-19 药物管理的快速/实时建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=日本关于 COVID-19 药物管理的快速_实时建议：更新指南（2021 年 9 月）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=785381c00232a186, title=日本关于 COVID-19 药物管理的快速/实时建议：更新指南（2021 年 9 月）, enTitle=Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021), guiderFrom=Acute Medicine & Surgery, authorId=0, author=, summary=自 2020 年初以来，2019 年冠状病毒病 (COVID-19) 已在全球范围内蔓延，但仍然没有解决的迹象。, cover=https://img.medsci.cn/2022117/1642434413106_5579292.png, journalId=0, articlesId=null, associationId=2309, associationName=日本脓毒症和感染性休克管理临床实践指南 , associationIntro=日本脓毒症和感染性休克管理临床实践指南 (J-SSCG) 2020 特别委员会, copyright=0, guiderPublishedTime=Tue Nov 16 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #1c1d1e;">自 2020 年初以来，2019 年冠状病毒病 (COVID-19) 已在全球范围内蔓延，但仍然没有解决的迹象。</span><span style="color: #1c1d1e;">日本脓毒症和感染性休克管理临床实践指南 (J-SSCG) 2020 特别委员会利用创建 J-SSCG 的经验制定了日本关于 COVID-19 药物管理的快速/实时建议。</span></p>, tagList=[TagDto(tagId=66473, tagName=药物管理), TagDto(tagId=99632, tagName=Covid-19)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4039, appHits=14, showAppHits=0, pcHits=231, showPcHits=4025, likes=0, shares=2, comments=3, approvalStatus=1, publishedTime=Mon Jan 17 23:42:59 CST 2022, publishedTimeString=2021-11-16, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Jan 17 23:47:13 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 11:26:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=日本关于 COVID-19 药物管理的快速_实时建议：更新指南（2021 年 9 月）.pdf)])
日本关于 COVID-19 药物管理的快速_实时建议：更新指南（2021 年 9 月）.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186726, encodeId=be931186e26c8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:05:39 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185474, encodeId=7e0311854e4c8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:53 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185473, encodeId=3ff011854e39d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:45 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-21 wjl066452

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186726, encodeId=be931186e26c8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:05:39 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185474, encodeId=7e0311854e4c8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:53 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185473, encodeId=3ff011854e39d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:45 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186726, encodeId=be931186e26c8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:05:39 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185474, encodeId=7e0311854e4c8, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:53 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185473, encodeId=3ff011854e39d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:23:45 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 微探

    学习学习

    0

相关指南

2018 台湾2型糖尿病合并心血管疾病患者药物管理共识

台湾心脏病学会(TSOC,Taiwan Society of Cardiology) · 2018-02-13

2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）

苏格兰校际指南网络(SIGN,Scottish Intercollegiate Guidelines Network) · 2017-11-30

2017 NICE指南：在社区接受成人护理的药物管理（NG.67）

暂未更新 · 2017-03-30